Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5640_Библиотеки_им_академика_М_И_Перельмана.pdf
Lipid-Based Drug Delivery Systems: Formulation and Applications 99
4.1.3 Pharmacokinetic
Profiling
Pharmacokinetics (PK) encompasses the study of a drug’s absorption, distribution, metabolism, and excretion (ADME) within the
body [59]. Pharmacokinetic profiling involves quantifying these
processes to understand how drugs behave in vivo. Key aspects of
pharmacokinetic profiling include:
Absorption Assessing how a drug enters
administration
(e.g., oral, intravenous, or topical) and determining
the bloodstream after
factors influencing absorption rates, such as solubility, permeability,
and formulation.
Distribution Examining how a drug
, including tissue penetration, plasma protein binding, and
body
distributes throughout the
crossing biological barriers to reach target sites.
Metabolism Investigating the biotransformation
of dr
ugs by
enzymes, primarily in the liver, into metabolites that may be pharmacologically active or inactive. Understanding metabolism aids in
predicting drug clearance and potential drug–drug interactions.
Excretion Evaluating the elimination
ugs and their metabo-
of dr
lites from the body through renal excretion, biliary excretion, or
other routes.
4.2 Imaging Techniques
Pharmacokinetic profiling employs various techniques such as
liquid chromatography-mass spectrometry (LC-MS), pharmacokinetic modeling, and in vivo studies in animal models or human
clinical trials [
60]. These studies provide crucial data on drug
concentrations over time, bioavailability, half-life, and clearance
rates, guiding dosing strategies and informing drug development
decisions. Permeability studies and pharmacokinetic profiling are
indispensable tools in drug development, offering insights into
how drugs interact with biological systems, their bioavailability,
and pharmacokinetic parameters [
61]. By integrating these studies
early in the drug discovery process, researchers can optimize drug
candidates, improve therapeutic outcomes, and enhance patient
safety.
Imaging techniques play a crucial role in various scientific disciplines, enabling researchers to visualize and study structures at
different scales with high resolution [
62]. Two prominent imaging
techniques are electron microscopy and fluorescence imaging, each
offering unique advantages and applications.
Multiphoton microscopy:
Multiphoton microscopy utilizes
longer-wavelength excitation light, allowing for deeper tissue penetration and reduced photodamage compared to traditional
100 Pratibha Yadav
fluorescence microscopy [63]. It is suitable for imaging thick specimens, such as live tissues and whole organisms, with minimal
distortion.
Fluorescence imaging has facilitated advancements in areas
such as molecular biology, neuroscience, drug discovery, and medical diagnostics [64]. It continues to evolve with the development
of advanced fluorescent probes, imaging modalities, and computational tools for image analysis.
In conclusion, electron microscopy and fluorescence imaging
are indispensable tools in scientific research, offering unparalleled
capabilities for visualizing and understanding the intricate structures and dynamics of biological systems, materials, and nanotechnologies [
65]. Their continued refinement and integration
with other techniques promise further breakthroughs in diverse
fields of study.
4.2.1 Electron Microscopy
Electron microscopy (EM) is a powerful imaging technique that
utilizes a beam of accelerated electrons to generate high-resolution
images of samples [66]. It surpasses the limitations of light microscopy by overcoming the dif fraction limit imposed by visible light,
allowing for the visualization of extremely small str uctures. There
are two main types of electron microscopy:
Transmission electron microscopy (TEM): In TEM, a beam of
electrons is transmitted through a thin specimen, interacting with
the sample to create an image. It provides ultra-high resolution,
allowing researchers to observe details at the nanoscale, such as
cellular organelles, nanoparticles, and crystalline structures
[
67]. TEM is widely used in materials science, biology, and
nanotechnology.
Scanning electron microscopy (SEM): SEM involves scanning a
focused electron beam across the surface of a sample, detecting
various signals such as secondary electrons, backscattered electrons,
and X-rays. This technique produces detailed three-dimensional
images of surfaces, offering insights into surface topography, composition, and morphology [
68]. SEM finds applications in metal-
lurgy, geology, biology, and materials research.
Both TEM and SEM have revolutionized scientific understanding by revealing intricate details of biological specimens, materials,
and nanoscale structures that were previously inaccessible with
conventional microscopy techniques [
69].
4.2.2 Fluorescence Imaging
Fluorescence imaging utilizes the fluorescence phenomenon,
where certain molecules emit light of a specific wavelength when
excited by light of a shorter wavelength. This technique is widely
employed in biology, medicine, and materials science for its ability
to selectively visualize specific molecules and structures within
complex samples [
70]. Key features of fluorescence imaging include
the following:
Lipid-Based Drug Delivery Systems: Formulation and Applications 101
Fluorescent Probes
Fluorescent dyes or genetically encoded fluorescent proteins are
used as probes to label specific targets within cells or tissues
[71]. These probes emit light upon excitation, enabling researchers
to track biological processes, study protein localization, and investigate cellular dynamics [72].
Confocal Microscopy Confocal microscopy is a fluorescence imaging technique that uses
a pinhole to eliminate out-of-focus light, resulting in highresolution, optical sectioning images [
73]. It is valuable for study-
ing cellular and tissue structures in three dimensions, providing
detailed insights into spatial relationships and interactions.
4.2.3 Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) stands as a cornerstone in
medical diagnostics, offering noninvasive and detailed images of
internal body structures. The technology relies on the principles of
nuclear magnetic resonance (NMR), where the alignment of
atomic nuclei in a magnetic field generates signals used to construct
images [
74]. MRI generates high-resolution images by detecting
the signals emitted by hydrogen nuclei (protons) in water molecules within the body. These signals vary based on tissue properties,
allowing for differentiation between organs, tissues, and abnormalities. MRI is widely utilized in medical fields for diagnosing
various conditions, including neurological disorders, musculoskeletal injuries, cardiovascular diseases, and tumors [
75]. Its ability to
provide detailed anatomical and functional information without
ionizing radiation makes it a preferred imaging modality in many
cases.
MRI continues to evolve with advanced techniques such as
functional MRI (fMRI) for studying brain activity, diffusionweighted imaging (DWI) for assessing tissue microstructure, and
magnetic resonance spectroscopy (MRS) for analyzing chemical
composition. The versatility and safety of MRI make it an indispensable tool in modern medicine, aiding in accurate diagnosis,
treatment planning, and monitoring of patient progress.
4.3 Stability Studies
Stability studies are essential in various fields, including pharmaceuticals, food science, and materials research, to assess product
quality, shelf life, and performance under different conditions
76]. Two critical aspects of stability studies are oxidative stability
[
and thermal stability.
4.3.1 Oxidative Stability Oxidative stability refers to a material’s resistance to oxidation, a
chemical reaction involving the loss of electrons that can lead to
degradation, spoilage, or loss of functionality [78]. Key points
about oxidative stability like vitamin E, vitamin C, and phenolic
compounds act as antioxidants, scavenging free radicals and inhibiting oxidation processes [
77]. Techniques such as accelerated
aging studies, oxygen exposure tests, and peroxide value
102 Pratibha Yadav
measurements are used to evaluate oxidative stability in pharmaceuticals, oils, polymers, and food products.
4.3.2 Thermal Stability
Thermal stability refers to a material’s ability to withstand temperature variations without significant degradation or changes in properties. Key aspects of thermal stability have specific temperature
ranges within which they maintain stability. Thermal analysis techniques like differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) help assess thermal behavior and
stability limits [
79]. Thermal stability is critical in industries such
as aerospace, automotive, electronics, and materials science, where
components and materials must withstand high temperatures during operation or processing. Adding thermal stabilizers, optimizing
formulations, and conducting thermal stress tests are strategies to
enhance thermal stability in materials and products. By conducting
stability studies, researchers and industries can ensure product reliability, safety, and performance under diverse environmental conditions, contributing to product quality assurance and regulatory
compliance.
5 Applications of Lipid-Based Drug Delivery Systems
5.1 Cancer Therapy
Cancer therapy has witnessed significant advancements in recent
years, with targeted drug delivery systems playing a crucial role in
improving treatment outcomes and reducing side effects
[
80]. Among these systems, lipid-based drug delivery stands out
for its versatility, biocompatibility, and ability to encapsulate a wide
range of therapeutics. Let’s delve into the applications of lipidbased drug delivery systems specifically in cancer therapy.
5.1.1 Targeted Drug Delivery
5.1.2 Combination Therapy
Lipid-based carriers can encapsulate chemotherapeutic drugs, peptides, nucleic acids, and imaging agents, allowing for targeted
delivery to cancer cells. Surface modifications with targeting ligands
such as antibodies, peptides, or aptamers enable specific recognition and uptake by cancer cells, reducing damage to healthy
tissues [
81].
Combination therapy, also known as combination chemotherapy or
polytherapy, is a treatment approach that involves using multiple
drugs or treatment modalities to target cancer cells through different mechanisms [
82]. This strategy aims to enhance treatment
efficacy, overcome drug resistance, and reduce the likelihood of
cancer cells developing resistance to individual drugs. Here’s an
overview of combination therapy for cancer and its significance in
clinical practice.
Lipid-Based Drug Delivery Systems: Formulation and Applications 103
5.2 Central Nervous System Disorders
5.2.1 Blood–Brain
Barrier Penetration
Central nervous system (CNS) disorders encompass a wide range of
conditions affecting the brain and spinal cord, including neurodegenerative diseases, psychiatric disorders, and neurological injuries
83]. Understanding the complexities of CNS disorders involves
[
exploring two crucial aspects: blood–brain barrier (BBB) penetration and neuroprotective effects. Let’s delve into these areas and
their significance in addressing CNS disorders.
The blood–brain barrier (BBB) serves as a protective barrier that
regulates the passage of substances between the bloodstream and
the brain. While it plays a vital role in maintaining CNS homeostasis, it also poses a challenge for drug delivery to treat CNS disorders. Overcoming BBB penetration barriers is essential for
effective therapeutic intervention [
84]. The BBB is composed of
specialized endothelial cells, tight junctions, pericytes, and astrocyte end-feet, which together restrict the entry of large molecules,
pathogens, and toxins into the brain. Many drugs, including large
molecules like proteins and peptides, have limited BBB permeability, hindering their efficacy in treating CNS disorders [
85].
Nanoparticles are utilized as carriers to transport drugs across
the BBB, exploiting mechanisms like receptor-mediated transcytosis or adsorptive-mediated transcytosis. Using focused ultrasound
in combination with microbubbles can temporarily disrupt the BBB
and facilitate drug delivery [
86]. BBB penetration is crucial for
delivering therapeutic agents, including neuroprotective compounds, neurotrophic factors, gene therapies, and small molecules,
to target brain regions affected by CNS disorders.
5.2.2 Neuroprotective Effects
Neuroprotection refers to strategies aimed at preserving, enhancing, or restoring neuronal function and structure, thereby slowing
down or preventing the progression of CNS disorders [
87]. Neu-
roprotective effects play a significant role in managing various conditions, including neurodegenerative diseases, stroke, traumatic
brain injury, and neuroinflammatory disorders.
Addressing central
nervous system (CNS) disorders requires a
comprehensive understanding of BBB penetration challenges and
the development of neuroprotective strategies. Overcoming barriers to BBB penetration enables effective drug delivery to target
brain regions, while neuroprotective effects aim to preserve neuronal function and mitigate disease progression [
88]. Continued
research into innovative drug delivery systems, neuroprotective
agents, and personalized treatment approaches holds promise for
improving outcomes and quality of life for individuals affected by
CNS disorders.
104 Pratibha Yadav
5.3 Antiviral and Antimicrobial Applications
5.3.1 Lipid Nanoparticles for Antiviral Drugs
Antiviral and antimicrobial therapies play crucial roles in combating
infectious diseases and improving public health. Advancements in
drug delivery systems have paved way for more effective and targeted treatments [
89]. In this context, lipid nanoparticles and
antibiotic delivery systems have emerged as promising approaches.
Let’s delve into their applications in antiviral and antimicrobial
treatments.
Lipid nanoparticles are nanoscale carriers composed of lipids or
lipid-like materials that can encapsulate and deliver various therapeutic agents, including antiviral drugs. Lipid nanoparticles provide
a protective environment for antiviral drugs, improving their stability and bioavailability. This is particularly important for fragile or
easily degraded drugs [
90]. Surface modifications of lipid nanopar-
ticles can facilitate targeted delivery to specific cells or tissues
infected by viruses, minimizing off-target effects and enhancing
therapeutic efficacy. Lipid nanoparticles can traverse cellular barriers and deliver antiviral drugs directly into infected cells, improving intracellular drug concentrations and inhibiting viral replication
91]. Some lipid nanoparticles can be engineered to interfere with
[
viral entry mechanisms, such as blocking viral attachment or fusion
with host cells, thereby exerting antiviral effects beyond drug
delivery.
For example, lipid-based nanocarriers like liposomes, solid lipid
nanoparticles (SLNs), and nanostructured lipid carriers (NLCs)
have been investigated for delivering antiviral drugs such as nucleoside analogs, protease inhibitors, and RNA interference (RNAi)
therapeutics.
5.3.2 Antibiotic Delivery Systems
Antibiotic delivery systems encompass various formulations
designed to improve the efficacy, safety, and targeted delivery of
antibiotics to combat bacterial infections. Here are key aspects of
antibiotic delivery systems:
Lipid nanoparticles and antibiotic delivery systems represent
innovative approaches in antiviral and antimicrobial treatments,
offering targeted drug delivery, enhanced drug stability, sustained
release, and improved therapeutic outcomes [
research and development in these areas hold promise for addressing challenges such as drug resistance, intracellular infections, and
localized infections, contributing to the advancement of infectious
disease management and public health initiatives [
6 Future Perspectives and Challenges
This section discusses the potential future directions of lipid-based
drug delivery systems and the challenges that researchers may face.
92]. Continued
93].
7 Conclusion
References
Lipid-Based Drug Delivery Systems: Formulation and Applications 105
It explores the integration of emerging technologies, personalized
medicine approaches, and the need for continuous innovation in
LBDDS development.
In conclusion, this chapter consolidates the latest advancements in
lipid-based drug delivery systems, providing lab-ready information
on formulation methodologies and applications. Understanding
these cutting-edge approaches is essential for the successful development of next-generation drug delivery systems with improved
therapeutic outcomes.
1. Saraf S, Jain A, Tiwari A, Verma A, Panda PK,
Jain SK (2020) Advances in liposomal drug
delivery to cancer: an over view. J Drug Deliv
Sci Technol 56:101549
2. Gershkovich P, Wasan KM, Barta CA (2008) A
review of the application of lipid-based systems
in systemic, dermal/transdermal, and ocular
drug delivery. Crit Rev Ther Drug Carrier
Syst 25(6):545–584
3. Paveli Z, Skalko-Basnet CN, Filipovi J,
Martinac A, Jalsenjak I (2005) Development
and in vitro evaluation of a liposomal vaginal
delivery system for acyclovir. J Control Release
106(1–2):34–43
4. Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery
to cells and tissue. Adv Drug Deliv Rev 55(3):
329–347
5. Constantinides PP (1995) Lipid microemulsions for improving drug dissolution and oral
absorption: physical and biopharmaceutical
aspects. Pharm Res 12:1561 –1572
6. Pouton CW (1997) Formulation of selfemulsifying drug delivery systems. Adv Drug
Deliv Rev 25:47–58
7. Pouton CW (2000) Lipid formulations for oral
administration of drugs: non-emulsifying, selfemulsifying and “self-microemulsifying” drug
delivery systems. Eur J Pharm Sci 11:S93–S98
8. Gursoy RN, Benita S (2004) Self-emulsifying
drug delivery systems (SEDDS) for improved
oral delivery of lipophilic drugs. Biomed
Pharmcother 58:173–182
9. Ezike TC, Okpala US, Onoja UL, Nwike CP,
Ezeako EC, Okpara OJ, Okoroafor CC, Eze
SC, Kalu OL, Odoh EC, Nwadike UG,
Ogbodo JO, Umeh BU, Ossai EC, Nwanguma
BC (2023) Advances in drug delivery systems,
challenges and future directions. Heliyon 9(6):
e17488.
2023.e17488. PMID: 37416680; PMCID:
PMC10320272
10. Chen X-Q, Gudmundsson OS, Hageman MJ
(2012) Application of lipid-based formulations
in drug discovery. J Med Chem 55(18):
7945–7956.
jm3006433
11. Puri A, Loomis K, Smith B, Lee JH,
Yavlovich A, Heldman E, Blumenthal R
(2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.
Crit Rev Ther Drug Carrier Syst 26(6):
523– 580.
critrevtherdrugcarriersyst.v26.i6.10. PMID:
20402623; PMCID: PMC2885142
12. Desai N (2012) Challenges in development of
nanoparticle-based therapeutics. AAPS J 14:
282–295.
012-9339-4
13. Ghasemiyeh P, Mohammadi-Samani S (2018)
Solid lipid nanoparticles and nanostructured
lipid carriers as novel drug delivery systems:
applications, advantages and disadvantages.
Res Pharm Sci 4:288–303.
10.4103/1735-5362.235156. PMID:
30065762; PMCID: PMC6040163
14. Mukherjee S,
lipid nanoparticles: a modern formulation
approach in drug delivery system. Indian J
Pharm Sci 1(4):349–358.
10.4103/0250-474X.57282. PMID:
20502539; PMCID: PMC2865805
15. D’Souza A,
tured lipid carriers (NLCs) for drug delivery:
https://doi.org/10.1016/j.heliyon.
https://doi.org/10.1021/
https://doi.org/10.1615/
https://doi.org/10.1208/s12248-
https://doi.org/
S, Thakur RS (2009) Solid
Ray
https://doi.org/
Shegokar R (2021) Nanostruc-
106 Pratibha Yadav
role of liquid lipid (oil). Curr Drug Deliv
18(3):249–270.
1567201817666200423083807
16. Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Jadidi Kouhbanani MA, Varma RS,
Marofi F, Jarahian M, Beheshtkhoo N (2021)
Liposomes: structure, biomedical applications,
and stability
lesterol. Front Bioeng Biotechnol 9:705886.
https://doi.org/10.3389/fbioe.2021.
705886. Retraction in: Front Bioeng Biotech-
nol. 2023 Sep 04;11:1285118. PMID:
34568298; PMCID: PMC8459376
17. Nsairat H, Khater D, Sayed U, Odeh F, Al
Bawab A, Alshaer W (2022) Liposomes: structure, composition, types, and clinical applications. Heliyon 8(5):e09394.
10.1016/j.heliyon.2022.e09394. PMID:
35600452; PMCID: PMC9118483
18. Guimara˜es D, Cavaco-Paulo A, Nogueira E
(2021) Design of liposomes as drug delivery
system for therapeutic applications. Int J
Pharm 601:120571.
1016/j.ijpharm.2021.120571
19. Jha S, Sharma PK, Malviya R (2016) Liposomal
drug delivery system for cancer therapy:
advancement and patents. Recent Pat Drug
Deliv Formul 10:177–183
20. Taher M, Susanti D, Haris MS, Rushdan AA,
Widodo RT, Syukri Y, Khotib J (2023) PEGylated liposomes enhance the effect of
cytotoxic drug: a review. Heliyon 9(3):
e13823.
2023.e13823. PMID: 36873538; PMCID:
PMC9976326
21. Numico G, Castiglione F, Granetto C,
Garrone O, Mariani G, Costanzo GD, Ciura
PL, Gasco M, Ostellino O, Porcile G, Merlano
M (2002) Single-agent pegylated liposomal
doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a
pilot trial. Lung Cancer 35:59–64.
org/10.1016/S0169-5002(01)00269-0
22. Feng H, Kang J-H, Qi S, Kishimura A, Mori T,
Katayama Y (2021) Preparation of a PEGylated
liposome that co-encapsulates l -arginine and
doxorubicin to achieve a synergistic anticancer
effect. RSC Adv 11:34101–34106.
doi.org/10.1039/D1RA06514A
23. Wang S, Chen Y, Guo J, Huang Q (2023)
Liposomes for tumor targeted therapy: a
review. Int J Mol Sci 24(3):2643.
org/10.3390/ijms24032643. PMID:
36768966; PMCID: PMC9916501
24. Dzieciuch-Rojek M, Poojari C, Bednar J,
Bunker A, Kozik B, Nowakowska M,
Vattulainen I, Wydro P, Kepczynski M, Ro
https://doi.org/10.1016/j.heliyon.
https://doi.org/10.2174/
parameters with emphasis on cho-
https://doi.org/
https://doi.org/10.
https://doi.
https://
https://doi.
´
g T
(2017) Effects of membrane PEGylation on
entry and location of antifungal drug itraconazole and their pharmacological implications.
Mol Pharm 14:1057–1070.
10.1021/acs.molpharmaceut.6b00969
25. Deshpande PP, Biswas S, Torchilin VP (2013)
Current trends in the use
tumor targeting. Nanomedicine (Lond) 8(9):
1509–1528.
13.118. PMID: 23914966; PMCID:
PMC3842602
26. Riaz MK, Riaz MA, Zhang X, Lin C, Wong
KH, Chen X, Zhang G, Lu A, Yang Z (2018)
Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a
review. Int J Mol Sci 19(1):195.
org/10.3390/ijms19010195. PMID:
29315231; PMCID: PMC5796144
27. Xing H, Hwang K, Lu Y (2016) Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics 6(9):
1336–1352.
15464. PMID: 27375783; PMCID:
PMC4924503
28. Alhamhoom Y, Kakinani G, Rahamathulla M,
Ali M, Osmani R, Hani U, Yoonus
Thajudeen K, Kiran Raj G, Gowda DV
(2023) Recent advances in the liposomal nanovesicles based immunotherapy in the treatment
of cancer: a review. Saudi Pharm J 31(2):
279–294.
2022.12.008. Epub 2022 Dec 24. PMID:
36942270; PMCID: PMC10023551
29. Lee Y, Thompson DH (2017) Stimuliresponsive liposomes for drug delivery. Wiley
Interdiscip Rev Nanomed Nanobiotechnol
9(5):e1450.
1450. Epub 2017 Feb 15. PMID: 28198148;
PMCID: PMC5557698
30. Gu Z, Da Silva CG, Van der Maaden K,
Ossendorp F, Cruz LJ (2020) Liposomebased drug delivery systems in cancer immunotherapy. Pharmaceutics 12(11):1054.
d o i . o r g / 1 0 . 3 3 9 0 /
pharmaceutics12111054. PMID: 33158166;
PMCID: PMC7694212
31. Salawi A (2020) Self-emulsifying drug delivery
systems: a novel approach to deliver drugs.
Drug Deliv 29(1):1811–1823.
o r g / 1 0 . 1 0 8 0 /10717544.2022.
2083724. PMID: 35666090; PMCID:
PMC9176699
32. Amara S,
iations in gastrointestinal lipases, pH and bile
acid levels with food intake, age and diseases:
possible impact on oral lipid-based drug delivery systems. Adv Drug Deliv Rev 142:3–15
https://doi.org/10.2217/nnm.
https://doi.org/10.7150/thno.
https://doi.org/10.1016/j.jsps.
https://doi.org/10.1002/wnan.
Bourlieu C, Humbert L (2019) Var-
https://doi.org/
of liposomes
https://doi.
https://
https://doi.
for
Lipid-Based Drug Delivery Systems: Formulation and Applications 107
33. Betageri GV (2019) Self-emulsifying drug
delivery systems and their marketed products:
a review. Asian J Pharm 13:73–84
34. Liao H, Gao Y, Lian C, Zhang
Yang Y, Ye J, Feng Y, Liu Y (2019) Oral
absorption and lymphatic transport of baicalein
following drug-phospholipid complex incorporation in self-microemulsifying drug delivery
systems. Int J Nanomedicine 14:7291–7306.
h t t p s : // d o i . o r g / 1 0.2147/IJN.
S214883. PMID: 31564878; PMCID:
PMC6735633
35. Hsieh CM, Yang TL, Putri AD, Chen CT
(2023) Application of design of experiments
in the development of self-microemulsifying
drug delivery systems. Pharmaceuticals (Basel)
16(2):283.
ph16020283. PMID: 37259427; PMCID:
PMC9958669
36. Li J, Wang Q, Xia G, Adilijiang N, Li Y, Hou Z,
Fan Z, Li J (2023) Recent advances in targeted
drug delivery strategy for enhancing oncotherapy. Pharmaceutics 15(9):2233.
o r g / 1 0 . 3 3 9 0 /
pharmaceutics15092233. PMID: 37765202;
PMCID: PMC10534854
37. Musielak M, Potoczny J, Bos
M (2021) The combination of liposomes and
metallic nanoparticles as multifunctional
nanostructures in the therapy and medical
imaging-a review. Int J Mol Sci 22(12):6229.
h t t p s : / /doi.org/10.3390/
ijms22126229. PMID: 34207682; PMCID:
PMC8229649
38. Sivadasan D, Sultan MH, Madkhali O,
Almoshari Y, Thangavel N (2021) Polymeric
lipid hybrid nanoparticles (PLNs) as emerging
drug delivery platform-a comprehensive review
of their properties, preparation methods, and
therapeutic applications. Pharmaceutics 13(8):
1 2 91.
pharmaceutics13081291. PMID: 34452251;
PMCID: PMC8399620
39. Seidu TA, Kutoka PT, Asante DO, Farooq MA,
Alolga RN, Bo W (2022) Functionalization of
nanoparticulate drug delivery systems and its
influence in cancer therapy. Pharmaceutics
14(5):1113.
pharmaceutics14051113. PMID: 35631699;
PMCID: PMC9145684
40. Municoy S, A´lvarez Echazu´ MI, Antezana PE,
Galdopo´rpora JM, Olivetti C, Mebert AM,
Foglia ML, Tuttolomondo MV, Alvarez GS,
Hardy JG, Desimone MF (2020) Stimuliresponsive materials for tissue engineering and
drug delivery. Int J Mol Sci 21(13):4724.
h t t p s : / /doi.org/10.3390/
ijms21134724. PMID: 32630690; PMCID:
PMC7369929
https://doi.org/10.3390/
h t t p s : / /doi.org/10.3390/
https://doi.org/10.3390/
Y, Wang B,
https://doi.
´
-Liedke A, Kozak
41. Xu W, Ling P, Zhang T (2013) Polymeric
micelles, a promising drug delivery system to
enhance bioavailability of poorly water-soluble
drugs. J Drug Deliv 2013:340315.
doi.org/10.1155/2013/340315.
Epub. PMID: 23936656; PMCID:
PMC3712247
42. Sa´nchez A, Mejı´a SP, Orozco J (2020) Recent
advances in polymeric nanoparticleencapsulated drugs against intracellular infections. Molecul es 25(16):3760.
org/10.3390/molecules25163760. PMID:
32824757; PMCID: PMC7464666
43. Alghamdi MA, Fallica AN, Virzı
Kesharwani P, Pittala` V, Greish K (2022) The
promise of nanotechnology in personalized
medicine. J Pers Med 12(5):673.
org/10.3390/jpm12050673. PMID:
35629095; PMCID: PMC9142986
44. Jamroz
45. Jain S, Kumar M, Kumar P, Verma J, Rosen-
46. Hong S, Choi DW, Kim HN, Park CG, Lee W,
47. Verma D, Gulati N, Kaul S, Mukherjee S,
48. Rahim MA, Jan N, Khan S, Shah H, Madni A,
49. Yadav
˙y M, Kudłacik-Kramarczyk S,
Drabczyk A, Krzan M (2024) Advanced drug
carriers: a review of selected protein, polysaccharide, and lipid drug delivery platforms. Int J
Mol Sci 25(2):786.
ijms25020786. PMID: 38255859; PMCID:
PMC10815656
holm JM, Bansal KK, Vaidya A (2023) Lipidpolymer hybrid nanosystems: a rational fusion
for advanced therapeutic delivery. J Funct Biomater 14(9):437.
jfb14090437. PMID: 37754852; PMCID:
PMC10531762
Park HH (2020) Protein-based nanoparticles
as drug delivery systems. Pharmaceutics 12(7):
6 0 4 .
pharmaceutics12070604. PMID: 32610448;
PMCID: PMC7407889
Nagaich U (2018) Protein based nanostructures for drug delivery. J Pharm 2018:1.
https://doi.org/10.1155/2018/9285854
Khan A, Jabar A, Khan S, Elhissi A, Hussain Z,
Aziz HC, Sohail M, Khan M, Thu HE (2021)
Recent advancements in stimuli responsive
drug delivery platforms for active and passive
cancer targeting. Cancers (Basel) 13(4):670.
h t t p s : / /doi.org/10.3390/
cancers13040670. PMID: 33562376;
PMCID: PMC7914759
Hartman JH, Russell LE (2021) Recent developments in in vitro and in vivo models for
improved translation of preclinical pharmacokinetics and pharmacodynamics data. Drug
Metab Rev 53(2):207–233.
10.1080/03602532.2021.1922435. Epub
h t t p s : / /doi.org/10.3390/
J, El Hassani M, Sodhi J, Lauschke VM,
https://doi.org/10.3390/
https://doi.org/10.3390/
https://doi.org/
https://
https://doi.
`
N,
https://doi.
108 Pratibha Yadav
2021 May 25. PMID: 33989099; PMCID:
PMC8381685
50. Amore BM, Gibbs JP, Emery MG (2010)
Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in
discovery settings.
Throughput Screen 13(2):207–218
51. Cho HJ, Kim JE, Kim DD, Yoon IS (2014) In
vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass
elimination of drugs: principles and applications. Drug Dev Ind Pharm 40(8):989–998
52. Poulin P, Kenny JR, Hop CE, Haddad S
(2012) In vitro—in vivo extrapolation of clearance: modeling hepatic metabolic clearance of
highly bound drugs and comparative assessment with existing calculation methods. J
Pharm Sci 101(2):838–851
53. Molavi F, Hamishehkar H, Nokhodchi A
(2020) Impact of tablet shape on drug dissolution rate through immediate released tablets.
Adv Pharm Bull 10(4):656–661.
org/10.34172/apb.2020.079. Epub. PMID:
33072542; PMCID: PMC7539314
54. Brown CK, Friedel HD, Barker AR, Buhse LF,
Keitel S, Cecil TL, Kraemer J, Morris JM,
Reppas C, Stickelmeyer MP, Yomota C, Shah
VP (2011) FIP/AAPS joint workshop report:
dissolution/in vitro release testing of novel/
special dosage forms. AAPS PharmSciTech
12(2):782–794.
s12249-011-9634-x. Epub 2011 June
18. PMID: 21688063; PMCID:
PMC3134645
55. Yang R, Wei T, Goldberg H, Wang W,
Cullion K, Kohane DS (2017) Getting drugs
across biological barriers. Adv Mater 29(37).
https://doi.org/10.1002/adma.201606596.
Epub. PMID: 28752600; PMCID:
PMC5683089
56. Koziolek M, Augustijns P, Berger C,
Cristofoletti R, Dahlgren D, Keemink J,
Matsson P, McCartney F, Metzger M,
Mezler M, Niessen J, Polli JE, Vertzoni M,
Weitschies W, Dressman J (2023) Challenges
in permeability assessment for oral drug product development. Pharmaceutics 15(10):2397.
h t t p s : / /doi.org/10.3390/
pharmaceutics15102397. PMID: 37896157;
PMCID: PMC10609725
57. Di L, Whitney-Pickett C, Umland JP,
Zhang H, Zhang X, Gebhard DF, Lai Y, Federico JJ, Davidson RE, Smith R (2011) Development of a new permeability assay using
low-efflux MDCKII cells. J Pharm Sci 100:
4974–4985.
22674
https://doi.org/10.1002/jps.
Comb Chem High
https://doi.
https://doi.org/10.1208/
58. Bagchi S, Chhibber T, Lahooti B, Verma A,
Borse V, Jayant RD (2019) In-vitro bloodbrain barrier models for drug screening and
permeation studies: an overview. Drug Des
Devel Ther 13:3591–3605.
10.2147/DDDT.S218708. PMID:
31695329; PMCID: PMC6805046
59. Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L,
Wang X, Lyu Y, Chen X, Liu K, Yu AM, Zuo Z,
Bi H (2019) Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B
9(6):1113–1144.
apsb.2019.10.001. Epub. PMID: 31867160;
PMCID: PMC6900561
60. Matsumoto T, Takiyama M, Sanechika S,
Nakayama A, Aoki K, Ohbuchi K, Kushida H,
Kanno H, Nishi A, Watanabe J (2020) In vivo
pharmacokinetic analysis utilizing
non-targeted and targeted mass spectrometry
and in vitro assay against transient receptor
potential channels of maobushisaishinto and
its constituent asiasari radix. Molecules
25(18):4283.
molecules25184283. PMID: 32962000;
PMCID: PMC7570662
61. Dahlgren D, Lennern€as H (2019) Intestinal
permeability and drug absorption: predictive
experimental, computational and in vivo
approaches. Pharmaceutics 11(8):411.
h t t p s : / /doi.org/10.3390/
pharmaceutics11080411. PMID: 31412551;
PMCID: PMC6723276
62. Lahoti HS, Jogdand SD (2022) Bioimaging:
evolution, significance, and deficit. Cureus
14(9):e28923.
cureus.28923. PMID: 36225412; PMCID:
PMC9541884
63. Borile G, Sandrin D, Filippi A, Anderson KI,
Romanato F (2021) Label-free multiphoton
microscopy: much more than fancy images.
Int J Mol Sci 22(5):2657.
10.3390/ijms22052657. PMID: 33800802;
PMCID: PMC7961783
64. Refaat A, Yap ML, Pietersz G, Walsh APG,
Zeller J, Del Rosal B, Wang X, Peter K (2022)
In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications. J Nanobiotechnol 20(1):450.
d o i . o r g / 1 0 . 1 186/s12951-02201648-7. PMID: 36243718; PMCID:
PMC9571426
65. Hickey SM,
Lazniewska J, Johnson IRD, Sorvina A,
Logan J, Martini C, Moore CR,
Karageorgos L, Sweetman MJ, Brooks DA
(2021) Fluorescence microscopy-an outline of
hardware, biological handling, and fluorophore
considerations. Cells 11(1):35.
https://doi.org/10.1016/j.
https://doi.org/10.3390/
https://doi.org/10.7759/
Ung B, Bader C, Brooks R,
https://doi.org/
https://doi.org/
https://
https://doi.